Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (1103)	8/9/1999 11:48:00 AM
From: LLCF	Respond to of 3202

This looks interesting: Cellomics Launches Cell-Based Drug Discovery Platform, ArrayScan II, for General Sale System Designed to Identify Highly Qualified Drug Candidates Earlier in the Drug Discovery Process - August 2, 1999 Pittsburgh, PA -- Cellomics™ , Inc. today announced the release of their proprietary, cell-based drug discovery platform, ArrayScan™ II for general sale. ArrayScan II was designed for "High Content Screening" (HCS), an approach to drug discovery that generates information-rich data regarding the effects of potential new drugs on various aspects of one or several cellular targets. ArrayScan II automatically measures detailed cellular responses so that highly qualified drug leads can be rapidly identified. The ArrayScan II was developed in collaboration with early pharmaceutical alliance partners over the last two years and was designed to shorten the time and decrease the cost to develop successful therapeutic candidates. ArrayScan II uses multicolor fluorescence-based reagents to follow and quantify the activity of components in living cells. Changes in marked (fluorescently labeled) cellular components over space and time are automatically analyzed using sophisticated image-based algorithms. The ArrayScan instrument can be purchased separately or can be integrated into a full-spectrum lead optimization program that includes assay development, "HitKit™" reagents, cell supply agreements, information management tools, and the Cellomics™ Database. The main advantage of ArrayScan II over other cell-based drug discovery methods is that ArrayScan provides more detailed and relevant information about the effects of compounds on a broad range of cellular properties. ArrayScan II permits the measurement of responses on, in, and even between cells with spatial resolution. Traditional cell-based screening systems measure an average response of a population of cells contained in each well of a microplate. "However ArrayScan II analyzes multiple parameters of each cell within a well individually and simultaneously," explained Michael A. Nemzek, Senior Vice President of Sales and Marketing at Cellomics. "Thus the ArrayScan II system provides tremendous benefits in many areas including target validation, drug candidate optimization, and early predictive toxicology." Another unique aspect of the ArrayScan II is that it can automatically place the raw data in a computer database for further data mining. The ArrayScan II is the first in a growing list of products that will accelerate the flow from generating sophisticated data, extracting new information, and creating new knowledge about the role of targets in cell function and the molecular basis of the interaction of compounds with cells. Cellomics is rapidly becoming the leader in producing a complete array of tools that will unlock the secrets of the new frontier of the cell in drug discovery. Cellomics™, Inc., a privately held corporation founded in October 1996, is focused on cell-based drug discovery. Cellomics' mission is to be the leader in generating high biological content data, information, and knowledge from cells using the integration of novel fluorescence-based biosensors, automated platforms, and cellular bioinformatics for faster and more effective drug discovery. The company has received financing from Interwest Partners, Axiom Venture Partners, Delphi Ventures, and Oxford Bioscience Partners. Cellomics additionally has an alliance with Carl Zeiss Jena GmbH, the world's leader in optical instrumentation and automation. This release is also posted at noonanrusso.com. For further information contact: Cellomics, Inc. Michael A. Nemzek Senior Vice President, Sales and Marketing 635 William Pitt Way Pittsburgh, PA 15238 Telephone: (412) 826-3600, x2677 E-mail: mnemzek@cellomics.com Noonan/Russo Communications Anjani Shah, Ph.D. Telephone: (212) 696-4455, x 340 E-mail: a.shah@noonanrusso.com DAK